



elene C. Carlson

Admitted only in Maryland Admitted only in Virginia Admitted only in Texas Practice Limited to

October 9, 2002

RECEIVED

OCT 1 1 2002

**TECH CENTER 1600/2900** 

(202) 371-2641 **INTERNET ADDRESS:** HCARLSON@SKGF.COM

WRITER'S DIRECT NUMBER:

Art Unit 1644

Commissioner for Patents Washington, D.C. 20231

> Re: U.S. Utility Patent Application

> > Appl. No. 09/458,298; Filed: December 10, 1999

**Inducing Cellular Immune Responses to MAGE2/3 Using Peptide and Nucleic Acid Compositions** 

Inventors: Fikes et al.

Our Ref: 2060.0130000/EKS/HCC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Copy of the Notice;
- Amendment and Submission of Substitute Sequence Listing Under 37 C.F.R. § 2. 1.825(a);
- 3. Five hundred ten 510 pages of a paper copy of the sequence listing;
- A computer readable disk copy of the sequence listing; and 4.
- 5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents October 9, 2002 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

James #42,613

Helene C. Carlson

Agent for Applicants Registration No. 47,473

HCC/PAC:drb Enclosures

::ODMA\MHODMA\SKGF\_DC1;62953;1 SKGF Rev. 2/15/02 dcw

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office
Address COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR 18623-014600 8697 09/458,298 12/10/1999 JOHN FIKES

26111

7590

09/09/2002

STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W., SUITE 600 WASHINGTON, DC 20005-3934

**EXAMINER** 

SCHWADRON, RONALD B

ART UNIT PAPER NUMBER 1644

DATE MAILED: 09/09/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

1 2 2002 SEP STERNE, KESSLER. GOLDSTEIN & FOX PLL C

DOCKETED Sequence Listing October 9, 2002 Sout Bru March 9, 2003

RECEIVED

OCT 1 1 2002

**TECH CENTER 1600/2900** 



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

**SERIAL NUMBER** 

**FILING DATE** 

FIRST NAMED APPLICANT

ATTORNEY DOCKET NO.

EXAMINER		
ART UNIT	PAPER NUMBER	

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

The communication filed on 10/1/2001 and 12/6/2001 is not fully responsive to the communication mailed 2/2/2000 for the reason(s) set forth on the attached Notice to Comply With the Sequence Rules or CRF Diskette Problem Report.

37 CFR 1.821(a) (post July 1998 sequence rules) requires sequence listings for amino acid sequences with four or more defined amino acids. No sequence listing has been submitted for sequences recited in Table III which have four or more defined amino acids.

Since the response appears to be bona fide, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Ron Schwadron, Ph.D., Art Unit 1644, whose telephone number is 703-308-4680.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

> RONALD B. SCHWADRON PRIMARY EXAMINER GROUP 1800 ( 60 a

Ron Schwadron, Ph.D. Art Unit 1644

RECEIVED

OCT 1 1 2002

TECH CENTER 1600/2900



Application No.: 09/458298

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.		
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).		
	3. A copy of the "Sequence Listing" in computer readable form has not been submit 37 C.F.R. 1.821(e).	tted as required by	
	4. A copy of the "Sequence Listing" in computer readable form has been submitted content of the computer readable form does not comply with the requirements of and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence".	37 C.F.R. 1.822	
	5. The computer readable form that has been filed with this application has been fo and/or unreadable as indicated on the attached CRF Diskette Problem Report. A computer readable form must be submitted as required by 37 C.F.R. 1.825(d).		
	6. The paper copy of the "Sequence Listing" is not the same as the computer reada "Sequence Listing" as required by 37 C.F.R. 1.821(e).	able from of the	
Ø	7. Other: See encloseD note		
Ap	plicant Must Provide:		
8	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing	<b>9</b> ".	
8	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.		
Ó	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).		
For	questions regarding compliance to these requirements, please conta	ict:	
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212	RECEIVE	
⊢or	Patentin software help, call (703) 308-6856	OCT 1 1 2002	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE TECH CENTER 1600/2900